
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is a promising biopharmaceutical company with strong financials and multiple promising drug candidates in their pipeline. Their recent FDA approvals and plans for label expansion and a new delivery method show potential for continued growth in the future. However, there is always a risk in drug development and competition in the market could impact their success.
Bears say
argenx is heavily reliant on one product, Vyvgart, for a majority of its revenue, making it vulnerable to potential competition or failure to demonstrate sustained efficacy in clinical trials. Their heavy investment in pipeline development may not pay off in the long run as the potential market for their treatments is small and niche. Additionally, potential pricing pressures in the biopharmaceutical industry could impact their profitability in the future.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares